Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Savolitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hutchmed Announces Breakthrough Designation for Orpathys & Tagrisso
    Hutchmed Announces Breakthrough Designation for Orpathys & Tagrisso

    11 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/12/2995863/0/en/HUTCHMED-Announces-Breakthrough-Therapy-Designation-in-China-for-ORPATHYS-and-TAGRISSO-Combination-in-Certain-Lung-Cancer-Patients-After-Disease-Progression-on-EGFR-Inhibitor-Thera.html

    GLOBENEWSWIRE
    11 Dec 2024
    Share Share
    Hutchmed's ORPATHYS® Maintains Inclusion In China’s NDL
    Hutchmed's ORPATHYS® Maintains Inclusion In China’s NDL

    28 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/28/2988577/0/en/HUTCHMED-Announces-Continued-Inclusion-of-ORPATHYS-savolitinib-in-the-National-Reimbursement-Drug-List-in-China-at-Current-Terms.html

    GLOBENEWSWIRE
    28 Nov 2024
    Share Share
    HUTCHMED Tagrisso Plus Orpathys High Response In Lung Cancer
    HUTCHMED Tagrisso Plus Orpathys High Response In Lung Cancer

    16 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/16/2963756/0/en/HUTCHMED-Announces-that-TAGRISSO-plus-ORPATHYS-demonstrated-high-clinically-meaningful-response-rate-in-lung-cancer-patients-with-high-levels-of-MET-overexpression-and-or-amplifica.html

    GLOBENEWSWIRE
    16 Oct 2024
    Share Share
    HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
    HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf

    08 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2942477/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-ESMO-Congress-2024-and-the-2024-World-Conference-of-Lung-Cancer.html

    GLOBENEWSWIRE
    08 Sep 2024
    Share Share
    China NMPA accepts for review Hutchmed’s sNDA for savolitinib
    China NMPA accepts for review Hutchmed’s sNDA for savolitinib

    29 Mar 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168216&sid=2

    PHARMABIZ
    29 Mar 2024
    Share Share
    HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment of NSCLC
    HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment of NSCLC

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/28/2853678/0/en/HUTCHMED-Announces-Savolitinib-sNDA-Accepted-in-China-for-Treatment-Na%C3%AFve-or-Previously-Treated-Patients-with-Locally-Advanced-or-Metastatic-MET-Exon-14-NSCLC.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share